AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)
AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)

Balance Sheet ADMS Quote Adamas Phar

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 24 91 57
ShortTermInvest 90 82 154
Cash 114 173 211
AccountReceivab 1 0 6
Inventories 0 2 5
DeferredIncomeT 0 0 0
OtherCurrentAss 1 1 2
TotalCurrentAss 117 179 228
PPE 4 6 6
AccumulatedDepr -1 -3 -2
NetPPE 3 3 4
EquityAndOtherI 22 3 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 1 3
TotalNonCurrent 25 7 6
TotalAssets 142 186 235
ShortTermDebt 0 0 2
AccountsPayable 4 4 7
TaxesPayable 0 0 0
AccruedLiabilit 2 7 8
DeferredRevenue 0 0 0
OtherCurrentLia 4 6 8
TotalCurrentLia 10 17 24
Debt 0 103 117
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 1 1 3
TotalNonCurrent 1 103 121
TotalLiabilitie 10 120 145
CommonStock 0 0 0
AdditionalPaidI 255 278 433
RetainedEarning -122 -212 -343
AccumulatedOthe 0 0 0
TotalStockholde 132 66 90
TotalLiabilitie 142 186 235
Adamas Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adamas Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.